SA Medicine 71号(2011年02月号)　特集「治療シリーズ -私はこうしている- Vol.8『循環器疾患』」

■『感染性心内膜炎』藤井洋子先生 著
1.Sykes JE, Kittleson MD, Pesavento PA, et al. Evaluation of the relationship between causative organisms and clinical characteristics of infective endocarditis in dogs: 71 cases (1992-2005). J Am Vet Med Assoc 2006;228:1723-1734.
2.Macdonald K. Infective endocarditis in dogs: diagnosis and therapy. Vet Clin North Am Small Anim Pract;40:665-684.
3.Sisson D, Thomas WP. Endocarditis of the aortic valve in the dog. J Am Vet Med Assoc 1984;184:570-577.
4.Peddle GD, Drobatz KJ, Harvey CE, et al. Association of periodontal disease, oral procedures, and other clinical findings with bacterial endocarditis in dogs. J Am Vet Med Assoc 2009;234:100-107.
5.MacDonald KA, Chomel BB, Kittleson MD, et al. A prospective study of canine infective endocarditis in northern California (1999-2001): emergence of Bartonella as a prevalent etiologic agent. J Vet Intern Med 2004;18:56-64.
6.Peddle GD, Boger L, Van Winkle TJ, et al. Gerbode type defect and third degree atrioventricular block in association with bacterial endocarditis in a dog. J Vet Cardiol 2008;10:133-139.
7.Quintavalla C, Mavropoulou A, Buratti E. Aortic endocarditis associated with a perforated septal membranous aneurysm in a boxer dog. J Small Anim Pract 2007;48:330-334.
8.Arai S, Wright BD, Miyake Y, et al. Heterotopic implantation of a porcine bioprosthetic heart valve in a dog with aortic valve endocarditis. J Am Vet Med Assoc 2007;231:727-730.
9.Sykes JE, Kittleson MD, Chomel BB, et al. Clinicopathologic findings and outcome in dogs with infective endocarditis: 71 cases (1992-2005). J Am Vet Med Assoc 2006;228:1735-1747.

■『三尖弁閉鎖不全症』藤井洋子先生 著
1.Sisson D KC, Darke PGG. Acquired valvular heart disease in dogs and cats. In: Fox PR SD, Moise NS., ed. Textbook of canine and feline cardiology. Philadelphia: WB Saunders, 1999;555-556.
2.Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006;229:1772-1778.
3.Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231.
4.Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-268.
5.Andelfinger G, Wright KN, Lee HS, et al. Canine tricuspid valve malformation, a model of human Ebstein anomaly, maps to dog chromosome 9. J Med Genet 2003;40:320-324.
6.Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol 2009;53:401-408.

■『僧帽弁閉鎖不全症』藤井洋子先生 著
1.Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23:1142-1150.
2.Beardow AW, Buchanan JW. Chronic mitral valve disease in cavalier King Charles spaniels: 95 cases (1987-1991). J Am Vet Med Assoc 1993;203:1023-1029.
3.Pedersen HD, Kristensen BO, Lorentzen KA, et al. Mitral valve prolapse in 3-year-old healthy Cavalier King Charles Spaniels. An echocardiographic study. Can J Vet Res 1995;59:294-298.
4.Oyama MA, Levy RJ. Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease. J Vet Intern Med;24:27-36.
5.Rush JE, Lee ND, Freeman LM, et al. C-reactive protein concentration in dogs with chronic valvular disease. J Vet Intern Med 2006;20:635-639.
6.Dell’italia LJ, Balcells E, Meng QC, et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997;273:H961-970.
7.Schultz D, Su X, Bishop SP, et al. Selective induction of the creatine kinase-B gene in chronic volume overload hypertrophy is not affected by ACE-inhibitor therapy. J Mol Cell Cardiol 1997;29:2665-2673.
8.Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. J Vet Intern Med 1995;9:243-252.
9.Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. J Vet Intern Med 1995;9:234-242.
10.Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998;213:1573-1577.
11.Fujii Y, Wakao Y. Spectral analysis of heart rate variability in dogs with mild mitral regurgitation. Am J Vet Res 2003;64:145-148.
12.Fujii Y, Orito K, Muto M, et al. Modulation of the tissue reninangiotensin-aldosterone system in dogs with chronic mild regurgitation through the mitral valve. Am J Vet Res 2007;68:1045-1050.
13.Kvart C, Haggstrom J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
14.Atkins CE, Keene BW, Brown WA, et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007;231:1061-1069.
15.Marcondes-Santos M, Tarasoutchi F, Mansur AP, et al. Effects of carvedilol treatment in dogs with chronic mitral valvular disease. J Vet Intern Med 2007;21:996-1001.
16.Adin DB, Taylor AW, Hill RC, et al. Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs. J Vet Intern Med 2003;17:632-636.
17.Hori Y, Katou A, Tsubaki M, et al. Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs. Am J Vet Res 2008;69:1664-1669.
18.Rationale and design of a randomized trial to assess the effects of diuretics in heart failure: Japanese Multicenter Evaluation of Long- vs Short-Acting Diuretics in Congestive Heart Failure (J-MELODIC). Circ J 2007;71:1137-1140.
19.Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249-261.
20.Haggstrom J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008;22:1124-1135.
21.Chetboul V, Lefebvre HP, Sampedrano CC, et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007;21:742-753.
22.Tissier R, Chetboul V, Moraillon R, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol 2005;5:43-51.
23.Ouellet M, Belanger MC, Difruscia R, et al. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med 2009;23:258-263.
24.Bernay F, Bland JM, Haggstrom J, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med;24:331-341.
25.Gelzer AR, Kraus MS, Rishniw M, et al. Combination therapy with digoxin and diltiazem controls ventricular rate in chronic atrial fibrillation in dogs better than digoxin or diltiazem monotherapy: a randomized crossover study in 18 dogs. J Vet Intern Med 2009;23:499-508.
26.Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006;229:1772-1778.
27.Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231.
28.Hochreiter C, Niles N, Devereux RB, et al. Mitral regurgitation: relationship of noninvasive descriptors of right and left ventricular performance to clinical and hemodynamic findings and to prognosis in medically and surgically treated patients. Circulation 1986;73:900-912.
29.Adin DB, Kittleson MD, Hornof WJ, et al. Efficacy of a single oral dose of isorsorbide 5-mononitrate in normal dogs and in dogs with congestive heart failure. J Vet Intern Med 2001;15:105-111.